Compare Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) vs Ermenegildo Zegna N.V. Ordinary Shares (ZGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) vs Ermenegildo Zegna N.V. Ordinary Shares — how do they compare? Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $19.4 (market cap $60.06B), while Ermenegildo Zegna N.V. Ordinary Shares trades at $12.8 (market cap $3.48B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 17.3× Ermenegildo Zegna N.V. Ordinary Shares's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays the higher dividend (3.33%). Which is the better fit depends on your goals — on Pluang, investors hold Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 6 Days and Ermenegildo Zegna N.V. Ordinary Shares for 0 Days on average.
| TAK | ZGN | |
|---|---|---|
Market Cap | $60.06B | $3.48B |
Volume | 2,925,042 | 1,076,161 |
Sector | Health | Consumer Cyclical |
52-Week High | $19.05 | $15.25 |
52-Week Low | $13.23 | $8.69 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $87.89B | $4.43B |
Dividend Yield | 3.33% | 1.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TAK trades at $18.52, down 0.86% on the day. The stock shows mixed signals with a bullish technical outlook from moving averages but neutral oscillators. Recent financials reveal a net income margin of -3.54% for 2026, though revenue remains stable near $4.6 trillion. Positive developments include the launch of ORZEYFUL for narcolepsy and FDA priority review for zasocitinib, highlighting a robust pipeline. Cash flow improved to $209.8 billion in 2026 from a negative position in 2025.
Outlook: TAK's strong analyst support (83% buy ratings) and promising drug pipeline offer growth potential, but profitability concerns and high P/E of 51.56 pose risks. Investors should weigh pipeline successes against current negative margins and elevated valuation.
ZGN trades at $12.94, up 2.7% with a neutral technical outlook. The stock shows mixed fundamentals with a high P/E of 38.5 but strong gross margins of 67.58%. Recent earnings beat expectations in three of the last four quarters, though Q2 2026 missed estimates. Analyst consensus is bullish with a $14.12 price target and 66.7% buy ratings. Revenue growth continues with 2025 reaching $1.92B, though net margins compressed to 3.98%.
ZGN presents a growth opportunity with expanding DTC momentum and margin potential, but faces valuation concerns and competitive pressures. The stock's upside depends on sustained earnings growth and successful execution of the retail-first strategy amidst fashion sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →About Ermenegildo Zegna N.V. Ordinary Shares
Ermenegildo Zegna N.V. is a luxury fashion group whose brands include Zegna, Thom Browne, and Tom Ford Fashion. The company operates a vertically integrated supply chain, sourcing wool from its own Australian farm through to finished garment production.
Read more on ZGN →
